SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Biotech Valuation
CRSP 56.87-2.3%Dec 5 9:30 AM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Ian@SI who wrote (6631)6/25/2002 9:17:03 PM
From: Czechsinthemail  Read Replies (1) of 52153
 
I'm not sure how much influence the ruling is likely to have beyond the particulars of this case. If it did have extended impact, I would think it might be particularly beneficial to SEPR, since concerns that many of their drugs might be regarded as questionable attempts to extend patent protection have weighed on the stock.

But in any case, the legal sparring between pharmas and generic companies is unlikely to be resolved by this ruling. It's a sad and costly game, but also an indication of how many dollars are involved in the outcome.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News